The milestone moves what Oculis describes as the first genotype-guided registrational trial in DED a step closer to a readout ...

Patients who say their eyes feel dry, gritty, or burning are among the most common in ophthalmology, and treating them well ...

The FDA has approved Alcon’s apraclonidine ophthalmic solution 0.125% (Brytly), an over-the-counter eye drop for redness ...

Prevent Blindness is observing its sixth annual Inflammatory Eye Disease (IED) Week from October 19 to 25, 2026, highlighting conjunctivitis and keratitis, thyroid eye disease (TED), and uveitis. 1 ...

LUCIA, the second of 2 pivotal phase 3 trials in neovascular (wet) age-related macular degeneration (AMD), missed its primary ...

The 2 complement inhibitors approved by the US Food and Drug Administration (FDA) for geographic atrophy (GA) secondary to ...

SpyGlass Pharma has reported 4-year interim results from the first-in-human (FIH) trial of its Bimatoprost Drug Pad-IOL System (BIM-IOL System), extending what the company describes as the “longest ...

At AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...

David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.

The FDA has approved Enspryng (satralizumab, Genentech) for thyroid eye disease (TED), making the drug the first subcutaneous ...

Taken together, these three responses point to gaps beyond the next therapy: in how academic medicine is valued, in what ...